Recall Radar
All recallsMedicine & devices

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2…

Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.

Class II Medicine & devices FDA May 13, 2026 Reached Texas
Read the official FDA notice →

What to do

Stop using the product and check it against the description above. Follow the remedy on the official notice; most recalls are refunded or replaced without a receipt. If you or a family member has already been affected, keep the packaging and the lot code — they're what a claim rests on later.

Details

Recalling company
Teva Pharmaceuticals USA, Inc — Parsippany, NJ
Severity
Class II — moderate
Reported
May 13, 2026
Quantity
2,200 kits
Recall number
D-0519-2026
Status
Ongoing
Source
FDA

Where it went

Nationwide in the USA

Other medicine & devices recalls

See every current recall on the live dashboard →